| |
Thursday, July 22, 2025 | 10am ET / 7am PT Join us to take an exciting look at the forefront of REMS transformation. Learn how leading technology, integrated strategies and operational excellence are redefining what’s possible. Gain the insights you need to reduce complexity, enhance compliance and deliver more value across the REMS lifecycle. Register now.
|
|
Today’s Big NewsJul 7, 2025 |
|
A pipeline-supporting marketing plan that includes proven tools, well-executed tactics, and a clear strategy are key to keeping your pipeline full of qualified leads. Access this valuable resource to discover how your marketing team can support your business development team in three essential areas: audience, storytelling, and performance. Download today!
|
|
| By Gabrielle Masson CSL is consolidating its R&D team in an effort to better position the organization “for long-term success in a rapidly evolving global environment.” |
|
|
|
By Conor Hale Andrew Hider will join the medtech after about eight years of leading ATS, a provider of factory automation solutions across multiple industries, including the life sciences. |
By Fraiser Kansteiner The FDA has approved sebetralstat under the brand name Ekterly as a new, oral treatment option for acute attacks of hereditary angioedema (HAE) in adults and children ages 12 years and older. The nod came just a few short weeks after the agency missed its June 17 target date originally established for the decision. |
By Kevin Dunleavy China's Dizal Pharmaceuticals has gained its first FDA approval, winning an accelerated nod for Zegfrovy to become the only U.S.-endorsed oral treatment for those with a rare type of non-small cell lung cancer. |
|
MedTech companies often launch groundbreaking devices, only to face slow adoption due to costly, time-intensive, and difficult-to-scale training. This whitepaper explores how Virtual Reality (VR) is changing that, helping teams engage physicians earlier, accelerate product adoption, and drive stronger commercial outcomes. Download now to learn more.
|
|
By Dave Muoio The lawsuit brought by the American Academy of Pediatrics, the Infectious Diseases Society of America and others seeks relief on COVID-19 vaccine recommendations for pregnant women and youth, but calls attention to the secretary's other controversial actions on vaccines. |
By Andrea Park As summer began and temperatures rose in June, so too did TV ad spending for Novo Nordisk’s Wegovy. |
By Angus Liu After several PD-1xVEGF competitors forged alliances with Big Pharma players, Summit Therapeutics, the frontrunner in this hot cancer drug field, is reportedly seeking its own deal. |
By Nick Paul Taylor Chugai Pharmaceutical has teamed up with Gero, offering up to $250 million for the chance to develop antibodies against age-related disease targets identified by its partner's AI-driven platform. |
By Conor Hale In its first year on the market, Farapulse brought in more than $1 billion in revenue. Now Boston Scientific aims to double its reach to the full afib population. |
By James Waldron Jasper Therapeutics is blaming a dud batch of its urticaria drug for derailing a phase 1/2 study of the candidate and raising the possibility of a restructuring to conserve cash. |
By Darren Incorvaia Months after announcing an M&A deal with AstraZeneca, EsoBiotec has released the first small slice of data on the cell therapy asset that attracted the Big Pharma’s attention. Four patients with multiple myeloma who received the Belgian biotech’s in vivo T-cell editing therapy all responded to treatment, with the cancer of two patients resolving completely. |
By Zoey Becker Future Pak's most recent bid for Theratechnologies won over the HIV drugmaker's board and a special sale committee. The CDMO has been chasing a Theratechnologies buyout since at least August of last year. |
By Conor Hale The company’s Felix NeuroAI Wristband aims to provide personalized stimulation therapy based on real-time feedback to help interrupt the involuntary shaking that can occur in the hands. |
Fierce podcastsDon’t miss an episode |
| | In this episode of "The Top Line," Teva CEO Richard Francis shares progress on the company’s “Pivot to Growth” strategy and what lies ahead. |
|
|---|
|
|
|
In all the “what if” chatter and fatigue around AI, predictive sales intelligence is a key opportunity that can easily be implemented and scaled to make omnichannel strategies even more potent. Our whitepaper explores the value of this capability, what role it plays in evolving HCP engagement trends, how to implement, and what to look for when engaging new partners and solutions. Download now.
|
|
| WhitepaperThis white paper outlines how we apply industry-backed practices and proprietary technologies to proactively safeguard sterility and performance. Sponsored by: Lonza |
| WhitepaperPresented by Blue Matter, strategic consultants in the life sciences Sponsored by Blue Matter Consulting |
| |
|
